IDiyas

For the Inventor, By the Inventor

Cadolzburg, Germany

Heidrun Engler

USPTO Granted Patents = 14

 

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 89(Granted Patents)


Company Filing History:

goldMedal9 out of 17 
 
Heumann Pharma Gmbh & Co.
 patents
silverMedal5 out of 23 
 
Ludwig Heumann & Co. Gmbh
 patents

Years Active: 1986-1993

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 5182294 - Imidazolyl propyl guanidine derivative and a pharmaceutical composition (1993-01-26),
2. 5108998 - Cardiotonic thiadiazine derivatives (1992-04-28),
3. 5025016 - Pyrimidine-thioalkyl pyridine derivatives, medicaments containing these (1991-06-18),
4. 4968683 - 6-oxo-pyridazine derivatives, a process for their preparation and (1990-11-06),
5. 4957920 - Benzimidazoles, and pharmaceutical preparations containing these (1990-09-18),
6. 4954501 - Piperazine substituted 6-phenyldihydro-3(2H)-pyridazinones, and (1990-09-04),
7. 4948802 - Guanidine carboxylic acid esters and pharmaceutical preparations (1990-08-14),
8. 4921856 - Dihydropyridazinone derivatives, a process for their preparation and (1990-05-01),
9. 4866066 - Thiomethylpyridine derivatives and their use for eliciting a (1989-09-12),
10. 4833141 - 4-[4-[[2-(halophenyl)-2-[1H-tr:azol(or (1989-05-23),
11. 4810715 - Imidazoyl-substituted thiomethylpyridine derivatives, method of (1989-03-07),
12. 4757080 - 1,4-dihydropyridine derivatives (1988-07-12),
13. 4732986 - Benzothiazole derivatives, processes for their preparation and (1988-03-22),
14. 4600721 - Pharmaceutical preparation (1986-07-15),

Title: Celebrating the Innovations of Heidrun Engler

Introduction

Heidrun Engler, a prominent inventor based in Cadolzburg, Germany, has made significant contributions to pharmaceutical chemistry with a focus on compounds beneficial for heart and circulatory health. With an impressive portfolio of 14 patents, Engler stands out as an innovator dedicated to advancing medical treatments.

Latest Patents

Among her latest breakthroughs, Engler has developed an imidazolyl propyl guanidine derivative that exhibits a unique combination of advantageous properties for treating heart and circulatory diseases. This innovative compound offers promising potential in the pharmaceutical industry. Additionally, her research on cardiotonic thiadiazine derivatives has led to the creation of new positive inotropic compounds. These compounds, characterized by a higher and more selective action than previously known alternatives, represent a significant advancement in the prevention and treatment of heart-related ailments.

Career Highlights

Heidrun Engler has worked with esteemed companies throughout her career, including Heumann Pharma GmbH & Co. and Ludwig Heumann & Co. GmbH. Her dedication and expertise have enabled her to forge a path of innovation, pushing the boundaries of pharmaceutical capabilities and improving patient outcomes.

Collaborations

Throughout her career, Engler has collaborated with talented individuals such as Helmut Schickaneder and Peter Morsdorf. These partnerships have played a crucial role in the development of her patents and the advancement of her research in cardiovascular treatments.

Conclusion

Heidrun Engler’s contributions to the field of pharmaceutical inventions reflect a commitment to innovation and improvement in healthcare. Her impressive array of patents showcases her dedication to finding solutions for critical health issues, particularly those concerning heart and circulatory conditions. Engler continues to inspire future generations of inventors and scientists in the ongoing quest for advanced medical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…